

Indonesia's Bio Farma secures UNICEF contract for oral polio vaccine type 2

04 October 2022 | News

Bio Farma has become the main supplier of oral polio vaccines (OPVs) in the world, and currently contributes 67% of the global OPV stockpile

Indonesia's PT Bio Farma (Persero), the holding company for pharmaceutical state-owned enterprises (SOEs), will export its novel Oral Polio Vaccine type 2 (nOPV2) having secured a purchase contract with the United Nations Children's Fund (UNICEF) for 2022 & 23.

Under the contract, Bio Farma will export its oral polio vaccines based on purchase requests from UNICEF via multilateral contract agreement for the years 2022 & 23. The nOPV2 vaccine received an Emergency Use of Listing (EUL) from the World Health Organization (WHO) in November 2020, the first ever vaccine certified for emergency use, adding to Bio Farma's portfolio of products that were already available globally. It was initially used to combat outbreaks of circulating vaccine-derived polio viruses (cVDPVs) in a number of African and East Mediterranean countries.

Bio Farma's nOPV2 vaccine is now distributed internationally, ex-Indonesia, as Indonesia has been polio-free since 2014. Target countries in Africa for the vaccine have included Algeria, Cameroon, Kongo, Ethiopia, Gambia, Ghana, Nigeria, Senegal, and Uganda. In Europe, it is administered in Israel and Ukraine, and in the Middle East, in Egypt, Iran, Somalia and Yemen.

In manufacturing the nOPV2 vaccine, Bio Farma collaborated with world-class institutions like the Bill and Melinda Gates Foundation (BMGF), the PATH, and the WHO.